Most Popular
-
1
[Herald Interview] 'Amid aging population, Korea to invite more young professionals from overseas'
![[Herald Interview] 'Amid aging population, Korea to invite more young professionals from overseas'](//res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/04/24/20240424050844_0.jpg&u=20240424200058)
-
2
Korea’s homegrown nanosatellite successfully launches into space
-
3
Nicaragua shuts down Seoul embassy
-
4
Rocket engine expert, ex-NASA exec to lead Korea's new space agency
-
5
SNU profs to suspend treatment for one day
![[Herald Interview] 'Amid aging population, Korea to invite more young professionals from overseas'](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/04/24/20240424050844_0.jpg&u=20240424200058)
-
6
SK hynix pledges W20tr to ramp up DRAM production at home
-
7
Hybe's multilabel system tested amid conflict with Ador
-
8
Over-50s, men, single-person households take up majority of those filing for bankruptcy
-
9
Ministry denies blame for Jamboree debacle
-
10
Pianist Cho Seong-Jin named Berlin Philharmonic's artist-in-residence
South Korean drug maker Daewoong Pharmaceutical Co. said Wednesday its generic antibiotic, Meropenem, was launched in the United States.
Meropenem, which is used in treatment for a wide range of diseases ranging from serious bacterial infection to general infection, was rolled out under the name "Daewoong Meropenem Inj" in the world's largest pharmaceutical market, it said.
In December 2012, the US Food and Drug Administration (FDA) accepted Daewoong Pharmaceuticals' application to sell the antibiotic, which is in reference to multinational pharmaceutical company AstraZeneca's Merrem.
It marks the first time for a generic drug manufactured by a local drug firm to be sold the US, company officials said.
"The company hopes the launch of Meropenem will boost the image of South Korean pharmaceutical companies in the US drug market," said Lee Jong-wook, vice president of Daewoong Pharmaceutical, in a press release. "The company will step up efforts to bring internationally competitive products."
The US market for antibiotics is expected to be worth $760 million by 2019. The carbapenem segment, which accounts for half of the entire US antibiotics market, will expand at an annual rate of 4.5 percent, the company said. (Yonhap)
